Unmet need for anticoagulation: Alternatives to warfarin?
=========================================================

Warfarin is highly effective in reducing stroke risk in patients with atrial fibrillation (AF). However, using warfarin is not easy; effort is needed to educate patients about drug and dietary interactions, and serial monitoring of the international normalization ratio (INR) is required. As a result, poor compliance is a big problem in warfarin use. A recent population-based cohort study showed that 43% of patients stopped warfarin within 3 years and 61% within 5 years.[@B1]

In addition, warfarin has a narrow therapeutic threshold, and the quality of anticoagulation has a critical influence on its effect. In a UK cohort study, warfarin therapy with a time in therapeutic range (TTR) of INR of less than 60% did not significantly reduce stroke risk compared to no antithrombotic therapy.[@B2] In a post hoc analysis of ACTIVE W (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events), in order to ensure the superiority of warfarin over clopidogrel plus aspirin the minimum projected TTR threshold was 58%.[@B3] While suboptimal doses lead to an increased risk of ischemic stroke, overdosing frequently results in hemorrhage that can be fatal. Even in the setting of clinical trials, the reported TTRs were only about two thirds.[@B4],[@B5],[@B6],[@B7] It also has been shown that eight adverse bleeding events are estimated to occur annually for every 100 patients treated,[@B8] and the underutilization of warfarin is in part due to concerns about hemorrhagic risk.

Lastly, the use of warfarin is particularly cumbersome in old subjects and in those with stroke. They are more vulnerable to bleeding complications that may be related with poor compliance, cognitive impairment, and the frequent presence of comorbid diseases that require polypharmacy and invasive procedures. In subjects undergoing invasive treatment, periprocedural management is difficult and carries a high risk for thromboembolism, partly because of the slow onset and offset of action (long half-life) of warfarin.

Therefore, more ideal anticoagulants are required that have a wide therapeutic range, a short half-life, and a predictable therapeutic effect with fixed or weight-based dosing, without significant food or drug interaction.[@B9]

Results from major randomized clinical trials of new oral anticoagulants
========================================================================

The first clinical study with warfarin was reported in 1955. In the meantime, several warfarin alternatives have been tested but failed to show benefits because of serious adverse effects, i.e., excessive bleeding with idraparinux[@B10] or hepatic dysfunction with ximelagatran.[@B11] New oral anticoagulants (NOACs) (dabigatran, apixaban, rivaroxaban, and edoxaban) were first introduced in 2005, for prophylaxis against venous thromboembolism after total hip or knee replacement surgery, and are now used to prevent and treat deep vein thrombosis and pulmonary embolism ([Table 1](#T1){ref-type="table"}).[@B12]

More recently, four large phase III randomized controlled trials of NOACs (RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48) have been completed in patients with non-valvular AF.[@B4],[@B5],[@B6],[@B7] Overall, NOACs were superior or non-inferior to warfarin in the prevention of ischemic stroke and systemic embolism, but superior to warfarin in reducing hemorrhagic stroke.[@B4],[@B5],[@B6],[@B7] NOACs may be more beneficial among patients with AF-related stroke or transient ischemic attack (TIA); a recent meta-analysis showed that NOACs significantly reduced stroke or systemic embolism, as well as hemorrhagic stroke or major bleeding, in patients with AF and previous stroke or TIA.[@B13] The relative risk reduction and the number needed to treat with NOACs vs. warfarin to reduce stroke/systemic embolism were estimated to be 14% and 134 patients; for avoiding hemorrhagic stroke the respective values were 57.9% and 139 patients.[@B13] Evidence from these trials forms the basis for national and international guidelines for the management of patients with non-valvular AF in clinical practice. Although aspirin was preferred in patients with a low-risk of stroke, new and safer anticoagulants may lead to lowering of the threshold for anticoagulation.[@B14]

The selection of antithrombotic agent (warfarin vs. NOACs) should be individualized on the basis of risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics such as renal function and TTR.[@B15] It would be unnecessary to switch from warfarin to NOACs in patients who already achieve stable and good INR control with warfarin. Good anticoagulation control (TTR\>70%) is associated with the best efficacy and safety of warfarin,[@B2] and the recent meta-analysis of the four phase III NOACs trials showed that there was a greater relative reduction in major bleeding with NOACs when the TTR was less than 66% than when it was greater.[@B16]

Viewing NOACs from Asian perspectives
=====================================

The use of NOACs may be more beneficial for Asian patients. First of all, it appears that Asians more often have cerebral small vessel disease, which is prone to bleeding. It has been shown that hemorrhagic stroke (intracerebral or subarachnoid hemorrhage), which accounts for 15% to 20% of strokes in whites,[@B17] is more frequent among Asians.[@B18] Death from hemorrhagic stroke is also much more common in Asians.[@B19] The prevalence of cerebral microbleeds, which increase the risk of intracerebral hemorrhage on anticoagulation, also appears to be higher in Asian than in white population.[@B20] The ethnic differences in bleeding-prone small artery disease are in part related with the high prevalence of uncontrolled hypertension or hypocholesterolemia in this region.[@B21] Ethnic differences in the salt sensitivity of intracranial hemorrhage (ICH) have also been addressed.[@B22] Whatever the reason, these small artery diseases predispose patients to cerebral bleeding when they are given antithrombotics; the presence of cerebral small artery diseases, such as lacunar infarcts, white matter ischemia or microbleeds, increases the risk of ICH in patients receiving antiplatelet agents[@B23] or anticoagulants.[@B24],[@B25] A recent study showed a high prevalence of warfarin-associated ICH in Asians, even if the INR levels were comparable; the hazard ratio for ICH was 4.06 for Asians, and 2 for Hispanics and blacks compared to whites.[@B26] Considering that NOACs have a lower bleeding risk than warfarin, the benefit of NOACs may be greater in Asian patients.

Second, Asians generally favor complementary treatment, such as herbal medication and healthy food. According to a study from Korea, 40% of patients who were initially treated in a large tertiary hospital tried additional herbal treatment after discharge.[@B27] This is in strong contrast to a report from Canada, where patients with cerebrovascular diseases rarely used alternative medicine.[@B28] A study from Hong Kong found that 26% of patients taking warfarin had ingested herbal remedies.[@B29] This behavior probably results in significant warfarin-drug/food interaction, poor INR control, and may at least in part explain the lower TTR achievement in Asian (mean 54.5%) than in non-Asian (66.2%) patients in the RE-LY trial.[@B30],[@B31] As Asians more often had a lower (rather than higher) INR level, another explanation would be that Asian physicians tend to target a relatively low INR because of the fear of bleeding complications. Indeed, Japanese guidelines recommend a target INR of 1.6-2.6 for Japanese people.[@B32] Whatever the reason, INR control is relatively poor in Asia, which also supports the notion that NOACs may be more suitable for Asians.

Finally, there has been evidence that population frequencies of genetic polymorphisms related with warfarin metabolism and action (e.g., CYP2C9 and VKORC1) differ according to ethnicities.[@B33],[@B34],[@B35] Apart from being linked to ethnic variations in the required warfarin dose, these differences may also partly explain the poor INR control and the higher risk of ICH among Asians.

Recent studies report that NOACs may be particularly valuable in Asians compared to non-Asians.[@B31],[@B36],[@B37] The RE-LY investigators reported that, among patients treated with warfarin, Asians (vs. non-Asians) had higher rates of ischemic stroke (by 2.1-fold) as well as hemorrhagic stroke (by 2.4-fold), despite similar blood pressure, younger age, and relatively lower INR values. The magnitude of the benefit from dabigatran in the prevention of ischemic stroke and hemorrhagic was greater in Asians than in non-Asians.[@B31] More recently, Chiang and colleagues reported a post-hoc analysis of the Asian population included in the RE-LY and ARISOTLE trials, which showed that, compared to non-Asians, Asians had a lower number needed to treat with NOACs vs. warfarin to reduce stroke/systemic embolism, and a higher number needed to treat to avoid hemorrhagic complications, favoring their use in Asians in terms of both efficacy and safety.[@B38]

Using NOACs in Asian stroke patients may be cost-effective
==========================================================

Cost-effectiveness analyses showed that NOACs are cost-effective relative to warfarin for stroke prevention in patients with AF and stroke/TIA.[@B39],[@B40],[@B41] Cost-effectiveness is associated with the cost of the drug, care costs, the loss of productivity due to disability following recurrent disease, individual patient risk for thromboembolism and bleeding, and the quality of anticoagulation control (i.e., TTR) which in turn is related to compliance, warfarin pharmacogenomics, and accessibility for regular INR tests.

We suggest that NOACs may be particularly cost-effective in Asian stroke patients for the following reasons. First, the risk of both recurrent thromboembolism and bleeding is higher in stroke patients than in patients without stroke. Moreover, as discussed above, Asians are at higher risk of warfarin-related ICH, a devastating condition, than Caucasians. Second, patients with AF-related stroke have a poorer control of INR than those without stroke, probably because of more severe neurological disability and a lack of access to frequent INR monitoring. It has been shown that most (\>70%) AF-related stroke patients have lobar or territorial infarcts,[@B42] and poor anticoagulation control is associated with the size of brain infarcts ([Figure 1](#F1){ref-type="fig"}).[@B43]

Thus, Asian stroke patients more often face problems in using warfarin: difficulty in maintaining INR and frequent bleeding complications. In this regard, NOACs appear to be particularly cost-effective for Asian stroke patients. However, NOACs are expensive drugs and studies focusing on the cost-effectiveness of NOACs in Asian stroke patients are unavailable. Nevertheless, given the considerations so far discussed, we propose that the reimbursement policy for the use of NOACs should be more generous for Asian stroke patients.

Viewing reimbursement guidelines for NOACs from strokologists\' perspective
===========================================================================

The guidelines for the reimbursement of NOACs are summarized in [Table 2](#T2){ref-type="table"}. In Japan, Taiwan, Norway, Switzerland, Iceland, and the United Arab Emirates, there is no restriction as long as NOACs are prescribed on-label. The reimbursement guidelines for NOACs in some European countries, including the UK, France, and Germany, are based only on the CHADS~2~ score (≥1). Other European countries and Canada include both CHADS~2~ score and the quality of anticoagulation control. For example, the provincial reimbursement guideline for NOACs in Canada includes (a) unable to tolerate warfarin, (b) INRs not well controlled on warfarin, or (c) unable to have INRs tested regularly, in patients with a CHADS~2~ score of ≥2.

The guidelines for the reimbursement of NOACs in Korea are similar to those of Canada, but the accessibility (ability to have INR tested regularly) is not considered. The criteria for \'inadequate anticoagulation\' appear to be too strict, especially during the maintenance period ([Table 3](#T3){ref-type="table"}). As a result, it is difficult to prescribe NOACs to stroke patients with severe disability, or those who live in remote areas (e.g., on an island) and are thus unable to test INR regularly. The guideline also recommends a frequent change of warfarin dose (at least 5 times during 6 months) to monitor INR. This is in conflict with a randomized study comparing TTR between warfarin dose assessment every 4 weeks vs. every 12 weeks, which showed that frequent dose changes to monitor INR are unnecessary and result in temporary fluctuation of the INR.[@B44] Moreover, the guidelines state that reimbursement can be allowed if patients have a major bleeding complication during warfarin treatment. From the strokologist\'s point of view this does not make sense, because warfarin-associated ICH is frequently fatal.

We understand that the strict guidelines can be attributed to the high cost of NOACs, which may adversely affects the health budget, but we would suggest that the guidelines be more generous to Asian stroke patients, who are particularly vulnerable to the adverse effects of warfarin. We suggest that this approach may be more cost-effective than not using NOACs, because recurrent ischemic stroke or ICH will be very costly in this rapidly aging society. As discussed above, cost-effectiveness studies on Asian stroke patients are unavailable and should be performed in the future to answer this question.

Conclusions
===========

AF is an emerging global epidemic in both high-income and low-income countries. Recently, the use of NOACs in AF patients has been rapidly increasing, but the cost of NOACs is unaffordable in low-income to middle-income countries. Consequently, the reimbursement guidelines for NOACs tend to be over-restrictive. However, the cost-effectiveness of NOACs will depend on the characteristics of patients as well as therapy pricing.

Asian countries are facing population aging at a pace that is unprecedented and an increasing burden of stroke, particularly AF-related stroke. AF-related stroke is more disabling and more fatal than other stroke subtypes, and is expected to increase substantially in the decades to come ([Figure 2](#F2){ref-type="fig"}). Compared to Caucasians, Asians more often develop hemorrhagic stroke and warfarin-related ICH, as well as any stroke in the case of patients with AF, and the benefit with NOACs vs. warfarin for preventing stroke and reducing anticoagulation-related ICH would be particularly high in Asians. Nevertheless, the current reimbursement guidelines are in general suboptimal. We suggest that guidelines for using NOACs should be more generous for Asian stroke patients.

In addition, as NOACs are expensive, continuous efforts should be made by healthcare providers and governors to find the ideal candidate for NOACs (most cost-effective group); this includes research to find genetic or clinical factors that predict the quality of anticoagulation control.[@B45],[@B46] Close communication is needed to arrive at a consensus decision regarding the coverage guideline for those patients who need NOACs, and to reduce the ever-increasing burden of AF-related stroke.
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![The relationship between stroke severity and the quality of anticoagulation control. (A) Most strokes related to atrial fibrillation are large cortical infarcts, especially among patients who were inadequately anticoagulated. (B) Patients with more severe neurological deficits had worse quality of anticoagulation. The time in therapeutic range of the international normalized ratio (INR) was negatively correlated with the baseline neurological deficits (*r*=-0.262, *P*=0.010). Figure modified from Oh et al.[@B42] NIHSS=National Institutes of Health Stroke Scale.](jos-16-73-g001){#F1}
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Current licensed indications for the new oral anticoagulants
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RE-LY, Randomized evaluation of long-term anticoagulant therapy (NCT00262600); ROCKET-AF, Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (NCT00403767); ARISTOTLE, Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (NCT00412984); AVERROES, Apixaban vs. aspirin in patients with atrial fibrillation and previous stroke or transient ischemic attack (NCT00496769); ENGAGE AF TIMI-48, Effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (NCT00781391); REMODEL, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement (NCT00168805); RE-NOVATE, Dabigatran etexilate vs. enoxaparin for prevention of venous thromboembolism after total hip replacement (NCT00168818); RE-MOBILIZE, Oral thrombin inhibitor dabigatran etexilate vs. North American enoxaparin regimen for prevention of venous thromboembolism after knee-replacement surgery (NCT00152971); RECORD, REgulation of Coagulation in ORthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism (NCT00329628, NCT00332020, NCT00361894, NCT00362232); ADVANCE, Apixaban Dose Orally vs. ANtiCoagulation with Enoxaparin (NCT00371683, NCT00452530, NCT00423319); RE-COVER, Dabigatran vs. warfarin in the treatment of acute venous thromboembolism (NCT00 291330, NCT00680186); RE-MEDY, Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism (NCT00329238); RE-SONATE, Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism (NCT00558259); EINSTEIN, Oral, direct Factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis or pulmonary embolism (NCT00439725, NCT00439777, NCT00439725); AMPLIFY, Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY (NCT00643201, NCT00633893); ATLAS ACS 2-TIMI, Anti-Xa Therapy to Lower cardiovascular events in addition to Aspirin with or without thienopyridine therapy in Subjects with Acute Coronary Syndrome (NCT00402597).
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The reimbursement guideline for new oral anticoagulants in Korea
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